Author:
Fujimura Tetsuya,Takahashi Satoru,Kume Haruki,Urano Tomohiko,Takayama Kenichi,Yamada Yuta,Suzuki Motofumi,Fukuhara Hiroshi,Nakagawa Tohru,Inoue Satoshi,Homma Yukio
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference31 articles.
1. Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
2. Cookson MS, Lowrance WT, Murad MH, Kibel AS. American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491–9.
3. Tannock IF, de Witt R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
5. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU15): a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14:149–158.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献